Status:
COMPLETED
Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborating Sponsors:
Sanofi
Conditions:
BPH
Erectile Dysfunction
Eligibility:
MALE
45-75 years
Phase:
NA
Brief Summary
Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED.
Detailed Description
The study will consist of a 30 day screening/washout phase at the end of which qualified subjects will be assigned to alfuzosin 10 mg tablets once a day. Subjects will be treated for 90 days. The tota...
Eligibility Criteria
Inclusion
- Males 45-75 years of age
- Confirmed diagnosis of BPH/lower urinary tract symptoms (LUTS) and ED
- Men with steady partner and who agree to attempt sex once a week.
Exclusion
- Prostate cancer
- Prostatitis
- Penile disease
- Cardiac co-morbidity
- Pre-existing co-morbid conditions
- History of sensitivity to the drug or similar drugs
- Enrollment in another clinical trial
- Impaired hepatic function
- Impaired renal function
- Mental conditions rendering subject unable to understand the study
- Subjects not likely to comply with protocol
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 8 2007
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00256399
Start Date
November 1 2005
End Date
May 8 2007
Last Update
August 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals of Cleveland
Cleveland, Ohio, United States, 44106